Real-time in vivo imaging and kinetic modeling transform static snapshots of radiotracer distribution into dynamic, quantitative narratives of pharmacokinetic behavior, revealing how a radiopharmaceutical is delivered, retained, and cleared from target tissues and organs over time. Protheragen provides state-of-the-art real-time in vivo imaging and kinetic modeling services that combine longitudinal micro-PET, micro-SPECT, and micro-CT acquisition with sophisticated compartmental and graphical analysis to extract physiologically meaningful parameters and accelerate your radiopharmaceutical from preclinical validation to clinical translation.
Real-time in vivo imaging, in the context of radiopharmaceutical development, refers to the continuous or serial acquisition of molecular imaging data following radiotracer administration, enabling the construction of time-activity curves (TACs) that describe the temporal evolution of radioactivity concentration in tissues of interest. Unlike static imaging, which captures a single time point and provides only semi-quantitative metrics such as standardized uptake value (SUV), dynamic imaging protocols reveal the full pharmacokinetic trajectory of a radiopharmaceutical—from initial vascular delivery and extravascular distribution to receptor binding, internalization, metabolic trapping, and eventual clearance. In preclinical settings, dedicated small-animal PET (micro-PET), SPECT (micro-SPECT), and CT scanners enable longitudinal dynamic imaging in rodent models with high spatial resolution and quantitative accuracy, providing data that are directly translatable to human clinical imaging protocols. These time-resolved measurements are essential for understanding the mechanism of action of a radiopharmaceutical, optimizing imaging protocols, and establishing the quantitative foundation for dosimetry and therapeutic dose planning.
Fig 1. Probes demonstrated as in vivo chemiluminescence imaging agents. (Haris, Uroob, et al., 2021)
Kinetic modeling is the mathematical framework used to interpret dynamic imaging data and extract physiologically relevant parameters that cannot be obtained from static images alone. Compartmental models—ranging from the one-tissue compartment model (1TCM) to the two-tissue compartment model (2TCM) and three-tissue compartment model (3TCM)—mathematically describe the exchange of radiotracer between plasma and tissue compartments, with rate constants (K1, k2, k3, k4) representing transport, binding, and metabolic processes. Graphical methods such as the Patlak plot and Logan plot provide computationally efficient alternatives for estimating net influx rate (Ki) and distribution volume (Vd) without iterative fitting. The choice of modeling approach depends on the tracer's biological behavior, the complexity of its interaction with the target, and the clinical or scientific question being addressed. For receptor-binding radiopharmaceuticals, kinetic modeling can distinguish between perfusion-related delivery and specific receptor binding, while for metabolic tracers such as 18F-FDG, it separates glucose transport from phosphorylation—insights that are critical for both diagnostic interpretation and therapeutic response assessment.
Protheragen understands that quantitative, time-resolved imaging data are essential for unlocking the full potential of a radiopharmaceutical. Our real-time in vivo imaging and kinetic modeling platform integrates cutting-edge small-animal PET, SPECT, and CT technology with advanced pharmacokinetic analysis tools to deliver robust, publication-quality data that illuminate the mechanistic behavior of your radiotracer from injection to elimination.
We apply one-tissue (1TCM), two-tissue (2TCM), and three-tissue (3TCM) compartment models to fit tissue TACs and estimate rate constants (K1, k2, k3, k4), distribution volume (Vd), binding potential (BP), and other physiological parameters. Model selection is guided by the tracer's known biology, goodness-of-fit statistics, and parameter identifiability analysis. Compartmental modeling is performed using validated software platforms with rigorous quality control to ensure reproducible and biologically meaningful parameter estimates.
For tracers with irreversible uptake, we apply Patlak graphical analysis to estimate the net influx rate constant (Ki) and distribution volume (Vd). For reversibly binding tracers, Logan graphical analysis provides estimates of distribution volume and binding potential. Reference tissue models—such as the simplified reference tissue model (SRTM)—enable quantitative analysis without arterial blood sampling by using a suitable reference region as an indirect input function, reducing study complexity and animal invasiveness.
For applications where model structure is uncertain or overly complex, we offer model-independent non-compartmental analysis (NCA) to estimate area under the curve (AUC), mean residence time (MRT), clearance (CL), and volume of distribution at steady state (Vss). Spectral analysis decomposes tissue TACs into a continuum of kinetic components, providing a data-driven approach to distinguish between different kinetic behaviors within heterogeneous tissues such as tumors with mixed viable and necrotic regions.
We leverage machine learning algorithms to automate image preprocessing, motion correction, organ segmentation, and noise reduction in dynamic PET/SPECT data. ML-based feature extraction from TACs enables prediction of therapeutic outcomes, absorbed dose estimates, and pharmacokinetic phenotypes. These AI-enhanced workflows improve throughput, reduce inter-operator variability, and unlock predictive insights that link preclinical imaging biomarkers to clinical efficacy.
Our real-time in vivo imaging and kinetic modeling service follows a systematic, milestone-driven workflow that ensures quantitative rigor, biological relevance, and regulatory defensibility. Each phase is designed to maximize data quality while minimizing animal usage, aligning with the 3Rs principles of replacement, reduction, and refinement.
Ready to unlock the quantitative potential of your radiopharmaceutical with real-time in vivo imaging and kinetic modeling? Contact us today to discuss your preclinical imaging requirements and learn how Protheragen can transform your dynamic data into actionable biological insights. Our imaging scientists and kinetic modeling specialists are prepared to design a customized study protocol tailored to your tracer's unique pharmacokinetic profile and development goals. Reach out to us now and discover why innovative radiopharmaceutical developers trust Protheragen as their partner for quantitative molecular imaging.
Reference